ArticleQuantitative imaging in medicine and surgery2022
Longitudinal pericardial adipose tissue changes in patients with breast cancer receiving anthracycline-based chemotherapy: a retrospective cohort study.
Article in Quantitative imaging in medicine and surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms.Journal of molecular and cellular cardiology · 2024Review
- Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer Survivors (The AIM Trial): Rationale, Design, and Methods.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pericardial adipose tissue (PAT) has been associated with adverse cardiac events. In this study, we evaluated changes of PAT in patients with breast cancer during and after anthracycline-based chemotherapy and explored the clinical variables associated with increases in PAT volume at the completion of chemotherapy. Methods: A total of 278 breast cancer patients who were receiving anthracycline-based chemotherapy were retrospectively enrolled. Their PAT volumes were measured using non-contrast chest computed tomography (CT) images from a dedicated workstation. We compared these volumes to their measurements at baseline, during different chemotherapy cycles, at and after chemotherapy completion. We identified the clinical variables associated with increases in PAT volume at chemotherapy completion using logistic regression analyses. Results: At the completion of chemotherapy, PAT volumes were shown to have increased compared to baseline measurements (87.67±45.09 Conclusions: Patients with breast cancer who undergo anthracycline-based chemotherapy can experience unfavorable PAT volume increases, which are maintained after the completion of treatment. Patients at risk of increases in PAT volume at chemotherapy completion can be identified based on clinical risk factors and targeted for interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.